The drug has shown strong results in phase 3 clinical trials, which are the basis for the new application to the FDA.

Intra-Cellular submitted its application to the FDA for Caplyta’s approval in major depressive disorder, potentially opening ...

A University of Queensland-led team analyzed data for 204 countries and territories, to assess global access to adequate ...

Depression is a common mental disorder. Some 300 million people in the world have it, or an estimated 3.8% of the population, ...

Major depressive disorder (MDD), commonly referred to as depression, is a serious medical condition that affects a person's ...

Discover how combining brain stimulation therapies improves depression treatment outcomes compared to single therapies, ...

Bright light therapy improves remission and response rates in nonseasonal depression, enhances antidepressant effectiveness, ...

Psilocybin effects on depression and anxiety are generally safe and well-tolerated, but researchers should focus on determining optimal dosage.

A new study by researchers from China and the UK explores the link between depression and menstrual pain (dysmenorrhea), a ...

Scientists found disrupted brain connectivity in youth depression, especially in networks tied to introspection and attention ...

Researchers have found 70 per cent of Australians diagnosed with major depressive disorder are not receiving even the minimal treatment necessary.

Cybin, Inc. ( (CYBN) ) has released its Q2 earnings. Here is a breakdown of the information Cybin, Inc. presented to its investors.Don't Miss ...